Form 4: Anebulo Pharmaceuticals Director Acquires Stock Options
SEC Form 4 Filing
Director Areta Kupchyk acquired stock options in Anebulo Pharmaceuticals, Inc. on April 4, 2025.
Summary
- On April 4, 2025, Areta Kupchyk, a director of Anebulo Pharmaceuticals, Inc., acquired stock options to purchase 27,647 shares of common stock.
- The options have an exercise price of $1.02 per share.
- 25,000 of the options vest on the earlier of April 4, 2026, or the date of the 2026 annual meeting of shareholders.
- The options expire on April 3, 2035.
- Following the transaction, Kupchyk directly owns options for 27,647 shares.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing regarding stock option grants, with no inherent positive or negative sentiment.
Industry Context
This is a standard disclosure of insider transactions, which is common in the pharmaceutical industry.
Stakeholder Impact
- The acquisition of stock options by a director could be perceived positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 04/04/2025 | Date of stock option acquisition |
| 04/04/2026 | Vesting date for 25,000 options (or date of 2026 annual meeting) |
| 04/03/2035 | Expiration date of the stock options |
| 04/07/2025 | Date of form submission |
Keywords
stock options, Form 4, director, ANEB, Anebulo Pharmaceuticals, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.